glucagon like peptide 1 glp 1 Glucagon-like peptide-1 GLP-1 Receptor Agonists Explained for

Int J Geriatr Psychiatry aprile

C.ChambersE

Clinical assessments were conducted every 3 months to evaluate efficacy, measured as percentage of total weight loss (%TWL), excess weight loss (%EWL), changes in BMI, and improvement in comorbidities, as well as tolerance, monitored for adverse effects including gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and discontinuation rates

GLP-1 is classified as an incretin hormone

The ability to "omit" failed results indicates a lack of security controls

2,3 However, safety concerns, particularly around cancer risk, have persisted since early rodent thyroid studies